Research and Development

NICE could be set to dramatically change its cost-effectiveness measure and help boost innovation in the UK, according to Sir …

Health secretary Alan Johnson kept an appointment to address the ABPI's annual conference yesterday despite the spread of swine flu …

Pfizer's Dr Ponni Subbiah is at the forefront of a revolution in the way the pharma industry views its business, …

Onyx Pharmaceuticals and its development partner Bayer have stopped a phase II trial of Nexavar in patients with late-stage melanoma, …

Newly-released data has added additional weight to the evidence for microdosing studies as a means to predict whether or not …

UK scientists will examine new samples of swine influenza as part of the global race to develop a vaccine against …

GlaxoSmithKline has pledged to closely monitor the swine flu outbreak that began in Mexico, and assist in access to treatment …

 Pfizer will work with researchers from University College London in the UK to try to develop stem cell-based therapies for …

AstraZeneca's Iressa is set to make a comeback after a European committee recommended its use for a sub-group of lung …

GSK and Pfizer have agreed to merge their respective HIV businesses, creating a single specialist entity with total pro-forma sales …

The FDA has approved Novartis's Afinitor for advanced renal cell carcinoma patients who have progressed after first-line Sutent or Nexavar …

France's Sanofi-Aventis is planning a major capital investment programme in Beijing in a bid to bolster its position in the …

NICE has approved Bayer's anti-clotting treatment Xarelto, bringing it into line with Boehringer Ingelheim's rival Pradaxa. Xarelto (rivaroxaban) was assessed …

An underlying principle for joint working between the NHS and the pharmaceutical industry is that it brings benefits to patients. …

Any positive effect on the pharmaceutical industry derived from the G20 summit and European Union summit will be indirect and …